Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Fink

Rheumatology Summerville, SC Medical Doctor

NPI 1699873885 CMS profile 167424

2001 2Nd Ave Ste 201, Summerville, SC 29486

Open in the dashboard

General payments

$2,857,826

403 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$11,535,985

6 holdings reported · through program year 2025

Through program year 2025, Gary Fink of Summerville, SC is reported in the CMS Open Payments database as having received $2,857,826 across 403 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $11,535,985 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,025,084 3
2024 General $432,647 1
2023 General $636,025 34
2022 General $456,013 107
2021 General $205,297 88
2020 General $101,043 63
2019 General $1,717 107
2025 Ownership $4,059,310 1
2024 Ownership $2,303,679 1
2023 Ownership $2,684,879 1
2022 Ownership $1,838,986 1
2021 Ownership $627,131 1
2019 Ownership $22,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Fink
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Gary Fink were reported at $1,025,084. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Gary Fink Rheumatology median Middle half National median
2019 $1,717 $744 $153–$2,687 $163
2020 $101,043 $462 $98–$2,027 $114
2021 $205,297 $531 $101–$2,153 $132
2022 $456,013 $627 $125–$2,303 $149
2023 $636,025 $741 $145–$2,524 $160
2024 $432,647 $830 $166–$2,660 $164
2025 $1,025,084 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. American Rheumatology Network, LLC $2,819,607 12 payments
  2. AbbVie, Inc. $32,148 58 payments
  3. Janssen Biotech, Inc. $1,357 84 payments
  4. Amgen Inc. $704 39 payments
  5. UCB, Inc. $452 29 payments
  6. E.R. Squibb & Sons, L.L.C. $425 25 payments
  7. Novartis Pharmaceuticals Corporation $380 25 payments
  8. Octapharma USA, Inc. $331 2 payments
  9. GlaxoSmithKline, LLC. $315 19 payments
  10. Pfizer Inc. $310 26 payments
  11. Other $1,796 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,445,147 2 payments
  2. Current or prospective ownership or investment interest $748,611 3 payments
  3. Royalty or License $624,221 1 payment
  4. Grant $28,834 5 payments
  5. Food and Beverage $7,403 386 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 1 payment
  7. Travel and Lodging $632 2 payments
  8. Education $477 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $31,931 44 payments
  2. SIMPONI ARIA $1,294 76 payments
  3. TREMFYA $1,071 56 payments
  4. STELARA $600 24 payments
  5. Cimzia $452 29 payments
  6. ORENCIA $425 25 payments
  7. COSENTYX $380 25 payments
  8. OCTAGAM IMMUNE GLOBULIN (HUMAN) $331 2 payments
  9. Enbrel $322 18 payments
  10. BENLYSTA $315 19 payments
  11. Other $3,537 204 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

403 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record